Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment
- Conditions
- Spondylarthropathies
- Interventions
- Other: Stool collection at the patient's home.Diagnostic Test: Blood test
- Registration Number
- NCT04540432
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
Idiopathic juvenile arthritis includes 20% of patients with arthritis with enthesitis or juvenile spondyloarthropathy. This is treated with anti-inflammatory drugs and then followed by biotherapy with DMARDs (Drugs Modifying the Activity of Rheumatic Disease) if the former are insufficient. Methotrexate (MTX) may also be used before these biotherapies. Recently, in adults, a particular profile of intestinal microbiota has been shown to alter the availability of MTX making it in efficient. Knowing that pediatric patients with juvenile spondyloarthropathy have an imbalance of their intestinal flora (dysbiosis) the investigators wanted to explore whether DMARDs could have a similar impact on the microbiota of these young patients and alter the response to treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 25
- Patients aged over 8 and under 17 years old (included).
- Patients diagnosed with arthritis with juvenile enthesitis according to the International League of Associations for Rheumatology (ILAR) criteria.
- Patients who haven't been treated by Methotrexate or biotherapy for at least 3 months.
- Patients who haven't been treated by cortisone for over a month.
- Patients whose parents have given written informed consent.
- Patients for whom the consent form has been signed by their legal guardian.
- Patients covered by the Social Security System or benefitting from private health insurance.
- Patients enrolled in another category 1 study or who have already taken part in a category 1 study within 3 months prior to inclusion.
- Patients who are within an exclusion period determined by another study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Profile AM Stool collection at the patient's home. Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate. Profile AMB Stool collection at the patient's home. Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate and then biotherapy if there is no improvement with methotrexate. Profile M Stool collection at the patient's home. methotrexate alone Profile A Stool collection at the patient's home. Patients on non-steroidal anti-inflammatory drugs. Profile B Blood test biotherapy alone Profile AB Blood test Patients on non-steroidal anti-inflammatory drugs followed by biotherapy. Profile AB Stool collection at the patient's home. Patients on non-steroidal anti-inflammatory drugs followed by biotherapy. Profile AM Blood test Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate. Profile AMB Blood test Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate and then biotherapy if there is no improvement with methotrexate. Profile M Blood test methotrexate alone Profile A Blood test Patients on non-steroidal anti-inflammatory drugs. Profile B Stool collection at the patient's home. biotherapy alone
- Primary Outcome Measures
Name Time Method Response to treatment in patients treated with non-steroidal anti-inflammatory drugs for 1 month followed by methotrexate for 5 months (Profile AM). Number of flare-ups. After 6 months of treatment The number of flare-ups in patients treated with non-steroidal anti-inflammatory drugs for 1 month followed by methotrexate for 5 months (Profile AM) will be noted.
Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Number of flare-ups. After 6 months of treatment The number of flare-ups in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) will be noted.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM).Number of species. After 1 month of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The number of species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Number of species detected in the intestinal microbiota. After 1 month of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department.The number of species detected in the intestinal microbiota will be recorded.
- the diversity index according to the number of species and the number of functional groups.Response to treatment in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Number of flare-ups. After 1 month of treatment The number of flare-ups in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A) will be noted.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Diversity of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The diversity index according to the number of species and the number of functional groups will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Number of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The number of species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Diversity of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The diversity index according to the number of species and the number of functional groups will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Distribution of species detected in the intestinal microbiota. After 1 month of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department.The distribution of the various bacterial species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Number of species detected in the intestinal microbiota. 24 hours after inclusion Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department.The number of species detected in the intestinal microbiota will be recorded.
Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) After 6 months of treatment The JADAS CRP clinical score will be used to rate the degree of activity of the disease. The Juvenile Arthritis Disease Activity Score (JADAS) is a recently developed composite tool for scoring disease activity in juvenile idiopathic arthritis. It is a composite disease activity score including four measures:
* the physician's global assessment of disease activity;
* the parent/guardian's or patient's global assessment of overall wellbeing;
* number of joints with active arthritis; and
* C-reactive protein (CRP) which has been determined as an alternative inflammatory marker to the Erythrocyte Sedimentation Rate ESR. JADAS-CRP was calculated similarly to the original JADAS as the simple sum of its four components, yielding a global score of 0-40, 0-57 and 0-101 depending on the joint count used for the JADAS10-CRP, JADAS27-CRP and JADAS71-CRP, respectively.Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Diversity of species detected in the intestinal microbiota. After 1 month of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department.The diversity index according to the number of species and the number of functional groups will be recorded.
Response to treatment in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A) After 1 month of treatment The JADAS CRP clinical score will be used to rate the degree of activity of the disease. The Juvenile Arthritis Disease Activity Score (JADAS) is a recently developed composite tool for scoring disease activity in juvenile idiopathic arthritis. It is a composite disease activity score including four measures:
* the physician's global assessment of disease activity;
* the parent/guardian's or patient's global assessment of overall wellbeing;
* number of joints with active arthritis; and
* C-reactive protein (CRP) which has been determined as an alternative inflammatory marker to the Erythrocyte Sedimentation Rate ESR. JADAS-CRP was calculated similarly to the original JADAS as the simple sum of its four components, yielding a global score of 0-40, 0-57 and 0-101 depending on the joint count used for the JADAS10-CRP, JADAS27-CRP and JADAS71-CRP, respectively.Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Diversity of species detected in the intestinal microbiota. 24 hours after inclusion Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department.The diversity index according to the number of species and the number of functional groups will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Number of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The number of species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Distribution of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The distribution of the various bacterial species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Distribution of species detected in the intestinal microbiota. 24 hours after inclusion Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department.The distribution of the various bacterial species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Distribution of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The distribution of the various bacterial species in the microbiota will be recorded.
Response to treatment in patients treated with non-steroidal anti-inflammatory drugs for 1 month followed by methotrexate for 5 months (Profile AM) After 6 months of treatment The JADAS CRP clinical score will be used to rate the degree of activity of the disease. The Juvenile Arthritis Disease Activity Score (JADAS) is a recently developed composite tool for scoring disease activity in juvenile idiopathic arthritis. It is a composite disease activity score including four measures:
* the physician's global assessment of disease activity;
* the parent/guardian's or patient's global assessment of overall wellbeing;
* number of joints with active arthritis; and
* C-reactive protein (CRP) which has been determined as an alternative inflammatory marker to the Erythrocyte Sedimentation Rate ESR. JADAS-CRP was calculated similarly to the original JADAS as the simple sum of its four components, yielding a global score of 0-40, 0-57 and 0-101 depending on the joint count used for the JADAS10-CRP, JADAS27-CRP and JADAS71-CRP, respectively.Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB) After 6 months of treatment The JADAS CRP clinical score will be used to rate the degree of activity of the disease. The Juvenile Arthritis Disease Activity Score (JADAS) is a recently developed composite tool for scoring disease activity in juvenile idiopathic arthritis. It is a composite disease activity score including four measures:
* the physician's global assessment of disease activity;
* the parent/guardian's or patient's global assessment of overall wellbeing;
* number of joints with active arthritis; and
* C-reactive protein (CRP) which has been determined as an alternative inflammatory marker to the Erythrocyte Sedimentation Rate ESR. JADAS-CRP was calculated similarly to the original JADAS as the simple sum of its four components, yielding a global score of 0-40, 0-57 and 0-101 depending on the joint count used for the JADAS10-CRP, JADAS27-CRP and JADAS71-CRP, respectively.Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Number of flare-ups. After 6 months of treatment The number of flare-ups in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB) will be noted.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Number of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The number of species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Distribution of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The distribution of the various bacterial species detected in the intestinal microbiota will be recorded.
Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Diversity of species. After 6 months of treatment Patients will provide 2 stool samples (one for analysis and one for the biobank) taken at the patient's home, preserved at -20°C and transported in a coolerbag to the hospital. One sample will be frozen to -80°C for the biobank and one sample will be kept at -20°C at the pediatric department. The diversity index according to the number of species and the number of functional groups will be recorded.
- Secondary Outcome Measures
Name Time Method Weight of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 Recorded in kilos
B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB) After 6 months of treatment Pre- and post-therapeutic translocation and response to treatment (presence/absence: detection of DNA 16S in the blood, quantification by quantitative PCR and sequencing for identification).
C: Constitution of a biobank for Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 All blood and stool samples used for the study will be deposited in the biobank for reference.
Height of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 Recorded in cm.
A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) and the clinical stage of evolution of Juvenile Spondylarthitis. 24 hours after inclusion The description of the intestinal microbiota profile according to INSERM laboratory Unit 1047 will be correlated with the clinical stage of the disease (on remission or acute flare) before and after treatment.
Sex of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 Male/Female
Lifestyle of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 The investigators will record details of the patient's lifestyle:
* Brothers and sisters (number and date of birth of each one)
* Communities (date of entry)
* Contact with animalsAge of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 Recorded in years
Height of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 Recorded in cm.
Weight of Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 Recorded in kilos
Sex of Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 Male/Female
Food allergies in Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 The investigators will record details of patients' food allergies.
B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) After 6 months of treatment Pre- and post-therapeutic translocation and response to treatment (presence/absence: detection of DNA 16S in the blood, quantification by quantitative PCR and sequencing for identification).
C:Constitution of a biobank of samples from Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) After 6 months of treatment All blood and stool samples used for the study will be deposited in the biobank for reference.
Age of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 Recorded in years
Lifestyle in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 The investigators will record details of the patient's lifestyle:
* Brothers and sisters (number and date of birth of each one)
* Communities (date of entry)
* Contact with animalsDietary habits in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 The investigators will record details of all patients' dietary habits and, more particularly, note all foods which are excluded.
A: Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) and the clinical stage of evolution of Juvenile Spondylarthitis. After 6 months of treatment The description of the intestinal microbiota profile according to INSERM laboratory Unit 1047 will be correlated with the clinical stage of the disease (on remission or acute flare) before and after treatment.
C: Constitution of a biobank for Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate). After 6 months of treatment All blood and stool samples used for the study will be deposited in the biobank for reference.
Weight of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 Recorded in kilos
Weight of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 Recorded in kilos
Sex of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 Male/Female
Previous treatment in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 The investigators will record details of all treatment followed prior to diagnosis of juvenile spondylarthritis:
* NSAIDs : dosage and dates
* Corticoids : dosage and dates
* Antibiotics : dosage and dates
* DMARDs : dosage and datesDietary habits in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 The investigators will record details of all patients' dietary habits and, more particularly, note all foods which are excluded.
Age of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate biotherapy) At the inclusion visit on Day 0 Recorded in years
A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs alone (Profile A) and the clinical stage of evolution of Juvenile Spondylarthitis. After 1 month of treatment The description of the intestinal microbiota profile according to INSERM laboratory Unit 1047 will be correlated with the clinical stage of the disease (on remission or acute flare) before and after treatment.
A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM) and the clinical stage of evolution of Juvenile Spondylarthitis. After 6 months of treatment The description of the intestinal microbiota profile according to INSERM laboratory Unit 1047 will be correlated with the clinical stage of the disease (on remission or acute flare) before and after treatment.
A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy (Profile AMB) and the clinical stage of evolution of Juvenile Spondylarthitis. After 6 months of treatment The description of the intestinal microbiota profile according to INSERM laboratory Unit 1047 will be correlated with the clinical stage of the disease (on remission or acute flare) before and after treatment.
B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A) After 1 month of treatment Pre- and post-therapeutic translocation and response to treatment (presence/absence: detection of DNA 16S in the blood, quantification by quantitative PCR and sequencing for identification).
B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM) After 6 months of treatment Pre- and post-therapeutic translocation and response to treatment (presence/absence: detection of DNA 16S in the blood, quantification by quantitative PCR and sequencing for identification).
C: Constitution of a biobank for AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 All blood and stool samples used for the study will be deposited in the biobank for reference.
Previous treatment in Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 The investigators will record details of all treatment followed prior to diagnosis of juvenile spondylarthritis:
* NSAIDs : dosage and dates
* Corticoids : dosage and dates
* Antibiotics : dosage and dates
* DMARDs : dosage and datesDietary habits in Profile A patients (treated with non-steroidal anti-inflammatory drugs alone) At the inclusion visit on Day 0 The investigators will record details of patients' dietary habits and, more particularly, note all foods which are excluded.
Previous treatment in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 The investigators will record details of all treatment followed prior to diagnosis of juvenile spondylarthritis:
* NSAIDs : dosage and dates
* Corticoids : dosage and dates
* Antibiotics : dosage and dates
* DMARDs : dosage and datesHeight of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 Recorded in cm.
Previous treatment in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 The investigators will record details of all treatment followed prior to diagnosis of juvenile spondylarthritis:
* NSAIDs : dosage and dates
* Corticoids : dosage and dates
* Antibiotics : dosage and dates
* DMARDs : dosage and datesFood allergies in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 The investigators will record details of all patients' food allergies.
Food allergies in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 The investigators will record details of all patients' food allergies.
Lifestyle in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 The investigators will record details of the patient's lifestyle:
* Brothers and sisters (number and date of birth of each one)
* Communities (date of entry)
* Contact with animalsFood allergies in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate) At the inclusion visit on Day 0 The investigators will record details of all patients' food allergies.
Age of Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy) At the inclusion visit on Day 0 Recorded in years
Height of Profile AB patients (treated with non-steroidal anti-inflammatory drugs for then biotherapy) At the inclusion visit on Day 0 Recorded in cm.
Sex of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 Male/Female
Lifestyle in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 The investigators will record details of the patient's lifestyle:
* Brothers and sisters (number and date of birth of each one)
* Communities (date of entry)
* Contact with animalsDietary habits in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy) At the inclusion visit on Day 0 The investigators will record details of all patients' dietary habits and, more particularly, note all foods which are excluded.
Trial Locations
- Locations (3)
APHM, Hopital Nord
🇫🇷Marseille, France
Nîmes University Hospital
🇫🇷Nîmes, Gard, France
Montpellier University Hospital, Arnaud de Villeneuve Hospital
🇫🇷Montpellier, Hérault, France